Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer

NCT03067792 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT03067792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03067792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer
Lead sponsor
Yonsei University
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2014
Completion date
October 17, 2016
Enrollment
52 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

inoperable gastric cancer